Search / 537 results found

from
to
  • Updated

IRVINE, Calif., Jan. 27, 2022 /PRNewswire-PRWeb/ -- EmeritusDX, a rapidly growing cancer diagnostics and information company, today announced the launch of UTIDX™, a PCR based test used for the diagnosis and treatment of Urinary Tract Infections (UTI). The test includes the top 31 uropathogens associated with UTIs, 24 known Antibiotics Resistance Genes, and the phenotypic evaluation of Antibiotic Sensitivity to the 18 most appropriate antibiotics.

  • Updated

THURSDAY, Jan. 27, 2022 (HealthDay News) -- Receipt of a third COVID-19 mRNA vaccine dose is associated with increased vaccine effectiveness against COVID-19 hospitalization, according to research published in the Jan. 28 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.

  • Updated

SAN DIEGO, Jan. 27, 2022 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice's clinical oncology programs, including Cirtuvivint (SM08502).

  • Updated

THURSDAY, Jan. 27, 2022 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) concludes that current evidence remains insufficient for weighing the benefits and harms of screening for atrial fibrillation (AF). These findings form the basis of a final recommendation statement published in the Jan. 25 issue of the Journal of the American Medical Association.

  • Updated

THURSDAY, Jan. 27, 2022 (HealthDay News) -- In response to claims that a man was denied a heart transplant because he refused to get vaccinated against COVID-19, Brigham and Women's Hospital in Boston said Wednesday that its transplant policies mirror those used across the United States.

  • Updated

HAYWARD, Calif., Jan. 27, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the publication of an article reviewing the use of sufentanil sublingual tablet (SST; DSUVIA®) for pain medicine procedures by lead author Dr. Sarang Koushik in Current Pain and Headache Reports. Dr. Koushik is a board-certified anesthesiologist and Clinical Assistant Professor of Anesthesiology at the University of Southern California Keck School of Medicine.

  • Updated

ALAMEDA, Calif., Jan. 27, 2022 /PRNewswire/ -- Fluxion Biosciences announced that its BioFlux system was used in research on COVID-19 and its ability to lead to high levels of platelet coagulation and an increased risk of thrombosis. The first study, published by a team at the University of Pennsylvania School of Medicine, was released in May 2021 as a preprint in bioRxiv, and is titled "Signaling through FcgRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19". The second publication, published by a team at the University Hospital of Tuebingen in Blood Advances on January 10, 2022, is titled "Upregulation of cAMP prevents antibody-mediated thrombus formation in COVID-19."